drugset / Trial / NCT05784129

A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection

NCT05784129

Phase 3 Terminated 4 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness of guselkumab treatment compared with placebo (an inactive substance with no medicine) in preventing recurrence of Crohn's disease in participants after surgery.

Timeline

Start
2023-02-21
Primary completion
2023-09-29
Completion
2023-10-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Guselkumab Monoclonal antibody Subcutaneous

Indications